Non-small cell lung cancer · line 2 · Sotorasib monotherapy (KRAS G12C+ NSCLC, 2L+)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy	2
Track	standard
Linked regimen	`REG-SOTORASIB-KRAS`

ID	`IND-NSCLC-KRAS-G12C-MET-2L`
Type	Indication
Status	status not declared
Diseases	`DIS-NSCLC`
Sources	`SRC-ESMO-NSCLC-METASTATIC-2024` `SRC-NCCN-NSCLC-2025`

Notes

KRAS G12C 2L+ standard. 1L role pending (CodeBreaK 1L trials). Adagrasib alternative; preferred for brain mets (better CNS profile).

Used By

Indication

IND-NSCLC-2L-KRAS-G12C-SOTORASIB - IND-NSCLC-2L-KRAS-G12C-SOTORASIB